New publication has been released on congenital toxoplasmosis vaccine
Title : Synthetic parasites: a successful mucosal nanoparticle vaccine against Toxoplasma congenital infection in mice.
Ducournau et al. 2016. Future Microbiology Le et al. 2020. International Journal of Pharmaceutics.
Aim: Development of protein vaccine to prevent congenital infection is a major public health priority. Our goal is the design of mucosal synthetic pathogen inducing protective immune responses against congenital toxoplasmosis. Materials & methods: Mice were immunized intranasally, establishing pregnancy and challenging orally. Placental immune response, congenital infection, pup growth, parasitic load rates were studied. Results: Pups born to vaccinated infected dams had significantly fewer brain cysts, no intraocular inflammation and normal growth. Protection was associated with a placental cellular Th1 response downregulated by IL-6 and correlated with persistence of vaccine for few hours in the nose before being totally eliminated. Conclusion: Our vaccine conferred high protection against congenital toxoplasmosis. These results provide support for future studies of other congenital vaccine.
Access the publication : HERE
Stay tuned for more updates as we continue our mission to protect animal and human worldwide! 🐒 🌿